The biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml) and Xgeva (denosumab 70 mg/ml) for treating osteoporosis, Simponi (golimumab) for treating rheumatoid arthritis, and Eylea (aflibercept) against wet-age macular degeneration as well as two undisclosed proposed biosimilars for immunology and oncology.
